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Abstract: Vagus nerve stimulation (VNS) represents one of the main surgical options for 
the treatment of the refractory epilepsy in pediatric and adult patients. There are several 
mechanism involved in vagal nerve stimulation which could influence the 
pathophysiology of seizures like neuromodulation of the thalamic and subthalamic 
nuclei involved in seizure initiation and the modulation of the neurotransmitters pattern 
norepinefrin, GABA, and serotonin. The VNS system is composed of the implanted 
components (the generator, the lead with the electrodes attached) and the programming 
system components (programming wand and handheld computer). The authors present 
their experience with 81 patients diagnosed with refractory epilepsy, investigated, 
selected and implanted with vagal neurostimulators between December 2012 and 
January 2015 in Neurosurgery Clinic, "Bagdasar-Arseni" Emergency Hospital. The 
surgical technique and the potential pitfalls are described in detail. There were 20 
children (24,7%) and 61 (75,3%) adults in this series. There was no death in this series 
and no intraoperative incidence. One patient presented dysphagia postoperatively which 
completely remitted after two months of follow-up. The outcome in term of seizure 
frequency and severity was better for patients under 30 years compared with patients 
older than 30 years. VNS represents now a safe, quick and efficient surgical procedure 
with a minimum period of hospitalization and a short recovery period. The good results 
on long term improve the quality of life of the patients and facilitate the social and 
professional reinsertion. 
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Introduction 
Refractory epilepsy represents a severe 
clinic entity which involves a significant 
number of patients and has important 
economic and social implications. The 
consequences for the patients are numerous 
and severe and include: adverse effects with 
long-term AED use (1, 2-5), increased seizure 
severity (3), depression and anxiety (4), 
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increased mortality and morbidity (6-8), 
seizure-related injuries, and increased 
healthcare utilization (eg, ER visits, 
hospitalizations) (9-11). For all these patients 
the drug therapy fails and the epilepsy surgery 
remains the only option. One of the surgical 
techniques employed in the management of 
refractory epilepsy is vagus nerve stimulation. 
Bremmer at al in 1938 were the first to 
investigate the use of vagus nerve stimulation 
and they recorded evoked response in 
thalamus after the nerve stimulation. The first 
effects of vagal nerve stimulation in animal 
models of chemical induced epilepsy were 
demonstrated in 1985 (12), this method 
relieving the subject from seizures by 
desynchronizing the cortical activity and 
decreasing the length and frequency of the 
seizures. There are several mechanism 
involved in vagal nerve stimulation which 
could influence the pathophysiology of 
seizures (13-23). First it should be underlined 
that vagus nerve contains an important 
contingent of afferent fibers to the dorsal 
nucleus of the vagus nerve located at the level 
of medulla oblongata. These inputs are 
directed to the locus coeruleus located in pons. 
This structure has multiple connections with 
several important cerebral structures. One 
important connection is with thalamic nuclei. 
Another important connection is with 
amygdala and hippocampus. From the 
thalamus the nervous inputs are directed 
through the entire subcortical and cortical 
structures of the brain. Therefore, in the end 
the vagus nervous stimuli are able to modulate 
the electric activity through the entire brain 
and to induce the desynchronization of the 
EEG rhythms (21, 22). Also, it was 
demonstrated that vagus nerve stimulation 
works by neuromodulation of the thalamic 
and subthalamic nuclei involved in seizure 
initiation and by modifying the 
neurotransmitters pattern like norepinefrin 
(13,14, 19), GABA (15, 17, 18), serotonin and 
aspartate (16, 17). The neurotransmitters 
pattern is regulated in hippocampus through 
the over expression of brain derived 
neurotrophic factor and fibroblast growth 
factor (24). Another important mechanism of 
action of vagus nerve stimulation is 
represented by the influence of the cerebral 
blood flow in thalamus and brain cortex, 
which indirectly may influence diffusely the 
electric activity of the entire brain cortex (20, 
23). 
The VNS system is composed of the 
implanted components (the generator, the 
lead with the electrodes attached (Figure 1a)) 
and the programming system components 
(programming wand and handheld computer) 
(Figure 1b). 
There are three electrodes which are 
attached to the vagus nerve: one positive, one 
negative and a neutral (tethered) electrode 
(Fig. 1c). The electrodes are connected to the 
generator through a lead. The lead and the 
generator are placed subcutaneously. The 
generator can be interrogated wireless using a 
special emitter called wand. The wand is 
connected to a handheld computer. Using 
these tools the doctor can turn on, turn off and 
more important can interrogate the generator 
to see the status of the battery and the 
impedance. This parameter is very useful to 
verify intraoperatively and postoperatively if 
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the electrodes are properly placed.  
Postoperatively it can be checked if there is any 
discontinuity of the system. Another 
important parameters which can be set up 
using the computer programmer and the wand 
are: intensity of the current, pulse width, the 
duty cycle (signal on/off time) and the 
frequency. Tabel.1 shows the range of these 
parameters. 
 
 
Figure 1a - Implanted components of the VNS system. 1b. Programming system components. 1c. The electrodes 
of the VNS system 
 
TABEL 1 
The parameters of the VNS stimulation 
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Intraoperatively the system is checked to 
see the proper function of it, and the 
impendence is measure to verify the correct 
placement of the electrodes around the vagus 
nerve, then the system is turned off. The 
system will be turned on at approximately two 
weeks after operation, in order to be sure that 
there is no risk of infections. Then, the patients 
will be periodically called for follow-up 
(usually every two weeks) to progressively 
increase the parameters of stimulation until 
they reached the typical values showed in 
Tabel 1. The authors present here the first 
series of patients with refractory epilepsy 
operated and implanted with vagal 
neurostimulators in Romania, and describe 
the surgical technique and the preliminary 
results. 
Patients and methods 
Our study includes 81 patients diagnosed 
with refractory epilepsy, investigated, selected 
and implanted with vagal neurostimulators 
between December 2012 and January 2015 in 
Neurosurgery Clinic, "Bagdasar-Arseni" 
Emergency Hospital. We have implanted in all 
patients the latest model of vagal 
neurostimulator (model 103), excepting two 
patients operated in December 2012, for 
whom the previous model (model 102) was 
used. We perform in all cases a standard left 
latero-cervical surgical approach. We use an 
horizontal incision in the left latero-cervical 
region in one of the skin crest, located at 
approximately the midway between the 
sternum and mastoid tip (Figure 2). 
After skin incision and platysma muscle 
division, we identify the anterior border of 
sternocleidomastoid muscle and the 
omohyoid muscle (Figure 3) 
Depending of the individual anatomy, we 
traction the omohyoid muscle out of the 
surgical corridor, or we divide it. The cervical 
left vasculo-nervous complex (common 
carotid artery and internal jugular vein) is 
identified and then we perform a 
microsurgical dissection of the left vagus nerv 
(Figure 4). 
At that level, the vagus nerve is usually 
located between the common carotid artery 
(medially located) and the internal jugular 
vein (laterally located), but in deeper location. 
The surgical dissection is directed with great 
care to the connective tissue between the great 
vessels, using the microsurgical technique and 
optic magnification until the vagus nerve is 
identified. There are several principles which 
guide the vagus nerve dissection. First, we have 
to perform a minimum 3 cm long dissection of 
the nerve (ideally 5 cm). It is very useful to use 
two rubber pieces two anchor the nerve at the 
both ends of the portion of the nerve which is 
dissected (Figure 5). 
 
 
Figure 2 - The position of the skin incisions 
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Figure 3 - Intraoperative view of the platysma muscle 
dissection 
 
 
Figure 4 - The intraoperativ view of the common 
carotid artery and the internal jugular vein 
 
 
Figure 5 - The intraoperative view of the left vagus 
nerve 
Applying gently a moderate tension on the 
nerve, we keep the portion of the nerve above 
the common carotid artery and internal 
jugular vein. Second, in order to obtain a 
proper contact between electrodes and vagus 
nerve it is necessary to completely remove the 
connective tissue which surround the nerve. 
Third, it is very important to not allow the 
nerve to dry out. Therefore, the surgical field 
should be continuously irrigated with saline 
serum. After a minimum of 3 cm of the vagus 
nerve is dissected (ideally 5 cm), the electrodes 
can now be connected to the vagus nerve. A 
second incision is performed, usually located 
at the pre-pectoral area, then the leads is 
tunneled between this second incision and the 
latero-cervical incision in a way that the 
electrodes' end of the lead  is placed at the level 
of the cervical incision . 
Then, the electrodes are placed on the 
vagus nerve. There are, from proximal to 
distal, one anchor tether and two electrodes: 
one positive electrode and one negative 
electrode (Figure 6). 
 
 
 
Figure 6 - Intraoperative view of the electrodes 
placed on the left vagus nerve 
 
  
 
 
 
Romanian Neurosurgery (2015) XXIX 2: 150 - 159           155 
 
 
 
 
 
 
 
The order of electrodes placement depends 
on the surgeon's preference. The electrodes 
can be connected either from proximally to 
distally, or distally to proximally. After 
connecting the electrodes, a loop is made using 
the extra-length of the lead and the generator 
is inserted together with the extra-length of the 
lead in the subcutaneous pocket. At the end of 
the surgical procedure, before removing the 
sterile drapes, the system is checked to assure 
the proper function of it and also the correct 
positioning of the electrodes. 
Results 
There were 20 children (24,7%) and 61 
(75,3%) adults in this series (Graphic 1).
 
Graphic 1: The percents of the children and the adults of the cohort 
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The medium age was 25,2 years. The age distribution is represented in the graphic 2. 
 
 
Graphic 2: Age distribution of the patients in our series 
 
The gender distribution was: 39 females (48,1%) and 42 males (51,9%) (Graphic 3). 
 
Graphic 3: Gender distribution of the patients in our series 
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The average period of hospitalization was 3 
days. The medium follow-up period was 11,5  
months and the minimum follow-up period 
was 3 months postoperatively for all patients. 
There was no death in this series and no 
intraoperative incidence. One patient 
presented dysphagia postoperatively which 
completely remitted after two months of 
follow-up. Eleven patients (13,5%) 
experienced for several days postoperatively 
hoarseness, which remitted completely within 
one week postoperatively. There were 50 
patients under 30 years (61,7%) and 31 
patients over 30 years (38,3%) in our series. 
We noticed that the percent of patients with 
50% seizure frequency reduction was 58% (29 
patients) at the end of the follow-up period in 
patients under 30 years  compared with 48,4% 
(15 patients) in patients older than 30 years. 
Seven patients (8,6%) were seizure free at 6 
months postoperatively. 
Discussions 
VNS therapy was first approved for clinical 
use in 1994 in European Union and Canada, 
followed by the FDA approval in 1997 for USA 
market. It should be noticed that this therapy 
is approved to be used for all kind of drug 
refractory epilepsy, both partial and 
generalized seizures (especially for partial 
seizures with secondary generalization). In 
order to be selected for this form of therapy the 
patients should fulfill two major requirements: 
1. to be correctly diagnosed with drug 
refractory epilepsy (according with ILAE 
consensus definition) and 2. do not have a 
surgically resectable epileptic focus/foci. 
According with ILAE definition (published in 
2010) the drug refractory epilepsy is "absence 
of complete seizures control of a properly 
diagnosed epilepsy syndrome, for a period of 
at least 12 months, following an adequate trial 
of two tolerated and appropriately chosen 
antiepileptic drugs" (25). The second 
condition is that patients, after a complete 
evaluation (including video EEG and cortical 
and deep electrodes monitoring) should not 
have a surgically resectable focus/foci.   This 
means that it cannot be accurately identified 
the surgical focus/foci, or this/these are 
identified, but there are situated in eloquent 
areas of the brain. When the patients fulfills 
these criteria, they could be considered 
candidates for vagus nerve stimulation. 
Because more than 80% of the parasimpatic 
fibers which innervate the cord are part of the 
right vagus nerve, the left nerve is targeted for 
vagus nerve stimulation, in order to reduce to 
the minimum the cardiac side effects. 
Presently, the use of VNS goes beyond 
intractable epilepsy, its use for depression 
being well spread in USA. Since the FDA 
approval of vagal nerve stimulation in 1997 the 
refractory epilepsy gained a valuable treatment 
tool. Even if the cost is prohibitive for 
individuals, the efficacy of this treatment was 
proved in large scale trials. One of the largest 
meta-analysis in USA including 3321 patients 
from 74 clinical trials reported 50% reduction 
in seizures in half of the patients one year after 
the VNS surgery (26). Other series have 
communicated better results, with up to 10% 
becoming free of seizures at one year follow-
up in pediatric population (27). These data 
underline the importance of a correct surgical 
pre-evaluation of the patients and a correct 
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selection in order to obtain a better outcome. 
We also find that children and young adults 
(under the age of 30 year-old) have a better 
response to VNS therapy compared with older 
patients (over 30 year-old). 
A more recent meta-analysis included all 
the devices (51,882) implanted in USA from 
1997 to 2012 and studied a rare complication, 
vocal cord paralysis, found in 193 cases (28). 
In our series we noticed only one case of 
temporary vocal cord paralysis, which 
remitted after two months of follow-up. There 
are several side effects related with VNS 
therapy, and includes: dysphonia, dysphagia, 
hoarseness, cough and tingling sensation in 
the throat and all are related with stimulation. 
It is important to mention that the intensity of 
these side effects decrease in time and they are 
related with the parameters of the stimulation 
(29).  
Conclusions 
VNS represents now a safe, quick and 
efficient surgical procedure with a minimum 
period of hospitalization and a short recovery 
period. The outcome of the patients is better, 
in term of the frequency and severity of the 
seizures, for children and young adults (under 
the age of 30 year-old) compared with older 
patients. The good results on long term 
improve the quality of life of the patients and 
facilitate the social and professional 
reinsertion. 
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